Skip to search formSkip to main contentSkip to account menu

fosamprenavir

Known as: (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester, fos-amprenavir, fosamprenavir [Chemical/Ingredient] 
A prodrug form of amprenavir. In the body fosamprenavir is metabolized to amprenavir, a synthetic derivative of hydroxyethylamine sulfonamide that… 
National Institutes of Health

Related topics

Related topics

14 relations
Amprenavir or Fosamprenavir:Susc:Pt:Isolate:OrdQn:GenotypingFosamprenavir SodiumFosamprenavir calciumFosamprenavir:Susc:Pt:Isolate:OrdQn:Phenotyping

Broader (5)

Anti-HIV AgentsCarbamatesHIV Protease InhibitorsOrganophosphates

Narrower (2)

GW-433908Lexiva

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Survey of Antiretroviral Drug Resistance Pattern Among HIV-Infected Patients with Treatment Failure in Iran
Antiretroviral Therapy is classified in six classes and acquired great achievements in HIV inhibition, but this advantage can be… 
Review
2010
Review
2010
The Effect of Acid Reduction With a Proton Pump Inhibitor on the Pharmacokinetics of Lopinavir or Ritonavir in HIV‐Infected Patients on Lopinavir/Ritonavir‐Based Therapy
T management of HIV infection has improved greatly over the past decade with the development of several different classes of… 
2010
2010
Virologic and Immunologic Outcomes in Patients Switched from Amprenavir to Fosamprenavir in a Clinical Practice Setting
In a 24-week phase 4, non-randomized, open-label, single-arm study, 19 HIV-infected patients receiving amprenavir (APV)-based… 
2009
2009
Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Sir, We have read with great interest the article by Gatti et al. concerning the use of unboosted fosamprenavir in HIV-infected… 
2009
2009
Optimal fosamprenavir regimen to prevent lipid abnormalities.
We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naive monoinfectd… 
2008
2008
Pharmacokinetics of an Indinavir‐Ritonavir‐Fosamprenavir Regimen in Patients with Human Immunodeficiency Virus
Study Objective. To evaluate the pharmacokinetic compatibility of a ritonavir‐boosted indinavir‐fosamprenavir combination among… 
2008
2008
96-Week Efficacy/Safety Data Comparing Two Doses of Ritonavir (/r) to Boost Once-Daily (QD) Fosamprenavir (FPV), Used in Combination with Abacavir (ABC)/Lamivudine (3TC)
Subjects in the FPV/r100 tended to have better virologic responses at both 48 weeks and 96 weeks than did subjects in the FPV… 
2008
2008
Darunavir in patients who failed on fos-amprenavir: efficacy at week 48
of results 17 patients (pts) fulfilling the selection criteria were retrieved from our database. They had been exposed to a… 
2004
2004
Fosamprenavir: A novel protease inhibitor and prodrug of amprenavir
Fosamprenavir (Lexiva, GlaxoSmithKline/Vertex) is the latest protease inhibitor (PI) approved by FDA for the treatment HIV-1… 
2003
2003
Lexiva (fosamprenavir) approved.
The FDA approved a prodrug that becomes amprenavir in the body, but has practical advantages over amprenavir.